A randomized, double-blind, placebo-controlled, multicenter parallel-group dose ranging clinical trial to assess the efficacy and safety of Org 4419-2 in the treatment of obstructive sleep apnea/hypopnea syndrome
Latest Information Update: 06 Aug 2021
Price :
$35 *
At a glance
- Drugs ORG 4419 (Primary)
- Indications Sleep apnoea syndrome
- Focus First in man; Therapeutic Use
- Sponsors NV Organon
- 06 Aug 2021 New trial record